Redhill Gains Most in 7 Months on RHB-102 Clinical Trial Success
Redhill Biopharma Ltd. (RDHL) surged the most in almost seven months after the Israeli pharmaceutical company said a clinical trial of its RHB-102 drug against nausea and vomiting in cancer treatments was successful.
The shares jumped as much as 22 percent, the biggest intraday increase since September 2011, and were 16 percent up at 2.50 shekels as of 10:38 a.m. in Tel Aviv, giving the company a market value of 131 million shekels ($35 million).
To contact the reporter on this story: David Wainer in Tel Aviv at firstname.lastname@example.org
To contact the editor responsible for this story: Calev Ben-David at email@example.com
Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.